Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn's disease: a propensity score-matched multicenter retrospective cohort study. (PubMed, Crohns Colitis 360) - Sep 13, 2026 - "In real-world practice, risankizumab was associated with modestly more favorable outcomes in patients with prior advanced therapy exposure, whereas differences became more apparent at 24 months in advanced therapy-naïve patients. Prospective studies are needed to confirm these findings."
HEOR • Journal • Retrospective data • Cardiovascular • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Venous Thromboembolism • CRP
|
|
Bisher Sawaf; Elias Batikh; Kyrillos Mahrous Gerges; Miguel Regueiro; Mohammad Al-Haddad; Mohammed Abu-Rumaileh; Muhammed Elhadi; Nwal Hadaki; Shahem Abbarh; Umberto Battistin; Yusuf Hallak
|